Abstract：【Objective】To discuss the clinical efficacy and safety of gestrinone and levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of adenomyosis. 【Methods】One hundred and sixty-eight cases of adenomyosis in our hospital from February 2014 to March 2016 were selected and divided into the observation group and the control group by random number table method. The observation group was treated with LNG-IUS, while the control group with gestrinone. The degree of dysmenorrhea, uterine volume, endometrial thickness, menstrual volume, hemoglobin levels and adverse reactions were compared between the two groups before and after treatment.【Results】 Compared with the conditions before treatment, dysmenorrhea and menorrhagia of the two groups of patients after treatment were significantly relieved. Hemoglobin levels were significantly increased, and the dysmenorrhea, menorrhagia and anemia symptoms of the observation group were improved (P<0.05); Compared with the control group before treatment, the endometrial thickness and uterine volume of the observation group after treatment were significantly reduced (P<0.05); there was no significant difference in endometrial thickness and uterine volume in the control group before and after treatment (P>0.05); Compared with the control group, the incidence of adverse reactions was obviously lower in the observation group (P<0.05).【Conclusion】The effect of LNG-IUS in treatment of adenomyosis is significantly better than that of gestrinone, and it is safe and worthy of clinical application.
李旭卿;陶丽娜;任洪叶. 孕三烯酮与左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床疗效及安全性分析[J]. 医学临床研究, 2017, 34(1): 46-48.
LI Xu-qing, TAO li-na, REN Hong-ye. Clinical Efficacy and Safety of Gestrinone and Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in Treatment of Adenomyosis. JOURNAL OF CLINICAL RESEARCH, 2017, 34(1): 46-48.
[1] 周媛萍,吴晓云,董其音,等,GnRH -α 联合左炔诺孕酮宫内缓释系统治疗大子宫腺肌病的疗效观察[J].中国微创外科杂志,2013,13(11):1003-1004. [2] Kim DH,Park DS,Kim ML,et al.Clinical experiences of the levonorgestrel-releasing intrauterine system in Korean women with adenomyosis[J].Korean J Gynecol Endosc Minim Invasive Surg,2012,24(2):108-114. [3] 刘晓鹏,张永萍,杨荣阁,等.不同治疗方式对子宫腺肌病患者性生活及婚姻生活质量的影响[J].中国妇幼保健,2012,27(4):585-587. [4] Heikinheimo O,Gemzell-Danielsson K.Emerging indications for the levonorgestrel-releasing intrauterine system (LNGIUS)[J].Acta Obstet Gynecol Scand,2012,91(1):3-9. [5] Engemise SL,Willets JM,Taylor AH,et al.Changes in glandular and stromal estrogen and progesterone receptor isoform expression ineutopic and ectopic endometrium following treatment with thelevonorgestrel-releasing intrauterine system[J].Eur J Obstet Gynecol Reprod Biol,2011,157(1):101-106. [6] 刘小艳,罗静雯,杨合荣,等.3889 例左炔诺孕酮宫内缓释系统临床应用分析[J].实用妇产科杂志,2013,29(5):376-379. [7] Kim JY,No JH,Kim K,et al.Effect of myoma size on failure of thermal balloon ablation or levonorgestrel releasing intrauterine system treatment in women with menorrhagia[J].Obstet Gynecol Sci,2013,56(1):36-40. [8] 全晓广,余 琳.左炔诺孕酮宫内缓释系统联合孕三烯酮治疗子宫腺肌病的临床观察[J].北方药学,2015,12(6):134-135. [9] 冯泽旻.左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫腺肌病所致痛经的临床疗效分析[J].药物与人,2014,27(6):94. [10] 李燕华.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床价值[J].现代诊断与治疗,2012,23(11):1979.
2017, Vol. 34 
